Prognostic value and anti-tumor immunity role of TMED9 in pan-cancer: a bioinformatics study.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2024-10-31 Epub Date: 2024-09-11 DOI:10.21037/tcr-24-258

Haodi Wang, Yue Wang, Pengyu Tan, Yichi Liu, Sa Zhou, Wenjian Ma

{"title":"Prognostic value and anti-tumor immunity role of TMED9 in pan-cancer: a bioinformatics study.","authors":"Haodi Wang, Yue Wang, Pengyu Tan, Yichi Liu, Sa Zhou, Wenjian Ma","doi":"10.21037/tcr-24-258","DOIUrl":null,"url":null,"abstract":"Background: Transmembrane p24 trafficking protein 9 (TMED9) belongs to the TMED family, and its overexpression frequently induces cancer. Studies have demonstrated the association between the overexpression of TMED9 and cancer development and proliferative migration in cancers such as ovarian cancer, hepatocellular carcinoma, and breast cancer. However, there has been no study investigating the clinical value, biological function, and anti-tumor immune effects of TMED9 from a pan-cancer perspective. The aim of this study is to evaluate the prognostic value and anti-tumor immunity role of TMED9 across pan-cancers.Methods: We utilized R language along with The Cancer Genome Atlas (TCGA), UCSC Xena (University of California, Santa Cruz Xena Browser), Human Protein Atlas (HPA), and other datasets to investigate TMED9 expression in various tumors. The association between high TMED9 expression and clinical prognosis and patient survival was examined using the Kaplan-Meier method, log-rank test, as well as univariate and multivariate Cox regression analyses. Tumor Immune Estimation Resource 2.0 (TIMER2.0) and various algorithms were employed to explore the relationship between TMED9 and the tumor microenvironment (TME). Additionally, the biological function of TMED9 in cancer was investigated through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) analyses.Results: TMED9 was over-expressed in the majority of cancers. Patients exhibiting elevated TMED9 expression typically experienced diminished survival rates and unfavorable clinical outcomes. TMED9 played a role as a mediator in the aggressive phenotype of numerous tumors, actively engaging in various biological and signaling pathways linked to cancer development. TMED9 demonstrated the capacity to modulate the anti-tumor immune response in pan-cancer patients, exerting its influence on the infiltration levels of immune cells and cancer-associated fibroblasts (CAFs).Conclusions: TMED9 serves as a novel \"cancer indicator\" and \"clinical prognostic marker\", capable of reshaping the TME, impacting the immunotherapeutic response, and guiding precise treatments for cancers to a certain extent.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5429-5445"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543038/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-258","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transmembrane p24 trafficking protein 9 (TMED9) belongs to the TMED family, and its overexpression frequently induces cancer. Studies have demonstrated the association between the overexpression of TMED9 and cancer development and proliferative migration in cancers such as ovarian cancer, hepatocellular carcinoma, and breast cancer. However, there has been no study investigating the clinical value, biological function, and anti-tumor immune effects of TMED9 from a pan-cancer perspective. The aim of this study is to evaluate the prognostic value and anti-tumor immunity role of TMED9 across pan-cancers.

Methods: We utilized R language along with The Cancer Genome Atlas (TCGA), UCSC Xena (University of California, Santa Cruz Xena Browser), Human Protein Atlas (HPA), and other datasets to investigate TMED9 expression in various tumors. The association between high TMED9 expression and clinical prognosis and patient survival was examined using the Kaplan-Meier method, log-rank test, as well as univariate and multivariate Cox regression analyses. Tumor Immune Estimation Resource 2.0 (TIMER2.0) and various algorithms were employed to explore the relationship between TMED9 and the tumor microenvironment (TME). Additionally, the biological function of TMED9 in cancer was investigated through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) analyses.

Results: TMED9 was over-expressed in the majority of cancers. Patients exhibiting elevated TMED9 expression typically experienced diminished survival rates and unfavorable clinical outcomes. TMED9 played a role as a mediator in the aggressive phenotype of numerous tumors, actively engaging in various biological and signaling pathways linked to cancer development. TMED9 demonstrated the capacity to modulate the anti-tumor immune response in pan-cancer patients, exerting its influence on the infiltration levels of immune cells and cancer-associated fibroblasts (CAFs).

Conclusions: TMED9 serves as a novel "cancer indicator" and "clinical prognostic marker", capable of reshaping the TME, impacting the immunotherapeutic response, and guiding precise treatments for cancers to a certain extent.

查看原文本刊更多论文

TMED9在泛癌症中的预后价值和抗肿瘤免疫作用：一项生物信息学研究。

背景：跨膜 p24 转运蛋白 9（TMED9）属于 TMED 家族，其过表达经常诱发癌症。研究表明，TMED9 的过表达与卵巢癌、肝细胞癌和乳腺癌等癌症的发展和增殖迁移有关。然而，还没有研究从泛癌症的角度调查 TMED9 的临床价值、生物功能和抗肿瘤免疫效应。本研究旨在评估 TMED9 在泛癌症中的预后价值和抗肿瘤免疫作用：我们利用 R 语言以及癌症基因组图谱（TCGA）、加州大学圣克鲁兹分校 Xena 浏览器（UCSC Xena Browser）、人类蛋白质图谱（HPA）和其他数据集来研究 TMED9 在各种肿瘤中的表达。利用卡普兰-梅耶法、对数秩检验以及单变量和多变量考克斯回归分析，研究了TMED9高表达与临床预后和患者生存之间的关系。研究采用了肿瘤免疫估算资源 2.0（TIMER2.0）和多种算法来探讨 TMED9 与肿瘤微环境（TME）之间的关系。此外，还通过基因本体（GO）、京都基因与基因组百科全书（KEGG）和基因组富集分析（GSEA）等方法研究了TMED9在癌症中的生物学功能：结果：TMED9在大多数癌症中过度表达。TMED9表达升高的患者通常生存率较低，临床预后较差。TMED9在许多肿瘤的侵袭性表型中扮演着介导者的角色，积极参与与癌症发展相关的各种生物和信号通路。TMED9能调节泛癌症患者的抗肿瘤免疫反应，对免疫细胞和癌症相关成纤维细胞（CAFs）的浸润水平产生影响：TMED9是一种新型的 "癌症指标 "和 "临床预后标志物"，能够重塑TME，影响免疫治疗反应，并在一定程度上指导癌症的精确治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.